Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

3rd Annual Stability Testing Conference

Next-Gen Sequencing Trends 2009

Competitor Analysis: c-MET/HGF Inhibitors

The Japanese Pharmaceutical Market 2008-2023

New Products

Japanese Pharmaceutical Market 2009-2024

3rd Annual Lyophilisation Conference

The Global Bioinformatics Market: Market size, forecasts and company profiles

Pharmaceutical Mergers and Acquisitions (PH133)

Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

The Global Analgesics Market 2009-2024

Competitor Analysis: Coagulation Factors

Competitor Analysis: PDGF-R Agonists and Antagonists

World Market for Addiction Disorders, 2009-2016

BioPortfolio | Kalorama Reports | Global Hepatitis Strategies

Global Hepatitis Strategies

The unrecognized importance, danger and costs of hepatitis in the 21st century cannot be understated or underestimated. While we were fortunate that, in the latter part of the 20th century, in that hepatitis was fairly well held in check, the impact of the disease on world society is still highly significant and now presenting a major crisis in public health circles.

In his exhaustive analysis of the potential diagnosis, screening and therapeutic markets for hepatitis, Ken Krul, PhD. advises companies to think on a global basis. In this study, Global Hepatitis Strategies Krul examines the potential market, epidemiology (hepatitis patient trends) and technology to provide a clear understanding of the opportunities and challenges awaiting companies competiting in this market.

As part of the market analysis this report includes

Extensive Statistics of Incidence and Prevalance of Hepatitis Across the 6 Major WHO Regions (Americas, Europe, Africa, Western Pacific, Southeast Asia, Eastern Mediterranean)

Etiology, Prophylaxis, and Therapy for Hepatitis A, B, C, D and E.

Theoretical Revenues for Diagnosis, Screening and Therapeutics representing the potential marketplace if all screening options are pursued.

Realistic Market Revenues representing the likely marketplace.

Global Distribution of Therapeutics and Diagnostics Revenues across Major 6 WHO regions

Over 40 Figures and Tables making information accessible.

Product managers, Marketing executives at pharmaceutical and diagnostic companies; as well as investment professionals are among those who will find this survey a critical resource.

Published: 01/08/07

Pages:200

PDF Format
Table of Contents
Price: $3,995.00 / €2,672.66

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions